drugset
drugset / Trial / NCT04984707

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

NCT04984707 ↗

Phase 1 Completed 40 enrolled Suzhou Kintor Pharmaceutical Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration

Timeline

Start
2019-01-28
Primary completion
2019-04-11
Completion
2019-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject KX0826 Unknown 3 mg Topical
Subject KX0826 Unknown 12 mg Topical
Subject KX0826 Unknown 48 mg Topical
Subject KX0826 Unknown 96 mg Topical

Indications

androgenetic alopecia